复星医药：控股子公司药品地舒单抗注射液获美国FDA注册批准

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, received FDA approval for its self-developed HLX14 injection, which is intended for the treatment of osteoporosis in postmenopausal women at high risk of fractures [1] Group 1: Product Development - The approved HLX14 injection comes in two specifications: 60mg/mL and 120mg/1.7mL [1] - HLX14 is aimed at treating osteoporosis and other indications consistent with the reference drug label [1]